Despite a surge in cannabis prescriptions for trauma survivors, the controlled evidence base remains far thinner than clinical adoption would suggest. This gap between practice and proof matters enormously for the millions of adults managing PTSD, where the stakes of ineffective or harmful treatment are high and where existing pharmacotherapies already carry significant limitations.
A scoping review synthesizing 26 studies — seven randomized controlled trials (RCTs) and 18 observational studies — and encompassing 3,598 patients found that only one RCT demonstrated a statistically significant clinical benefit: nabilone, a synthetic cannabinoid, reduced PTSD-related nightmares versus placebo. Two RCTs using inhaled or oral whole cannabis failed to outperform placebo on primary symptom outcomes. Two additional RCTs administering oral THC during fear-extinction paradigms documented neurobiological shifts — including increased ventromedial prefrontal cortex activation and reduced fear renewal — yet these changes did not translate into measurable clinical improvement. Trials of acute oral CBD showed minimal benefit, largely limited to transient mood effects. Observational studies generally reported symptom reductions, but these are subject to substantial confounding.
The divergence between the neurobiological signal and clinical non-improvement is arguably the most intellectually significant feature of this review. THC appears capable of modulating fear-circuit activity — consistent with the endocannabinoid system's known role in fear memory consolidation — yet that mechanistic plausibility has not converted into therapeutic efficacy under rigorous conditions. This pattern is a familiar hazard in psychiatry: promising biomarker changes that don't survive the translation to patient outcomes. The observational literature's positive lean likely reflects selection bias, the natural course of PTSD in treatment-seeking populations, and regression to the mean rather than genuine drug effect. Nabilone's isolated success warrants replication in larger, adequately powered trials before clinical guidelines shift. Until then, the prevailing guideline recommendation against routine cannabinoid use for PTSD remains empirically defensible, even as real-world prescribing accelerates in the opposite direction.